Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report

We reported the anesthetic management of remimazolam, a novel ultra-short-acting benzodiazepine, for a 21-month-old female with immune-mediated necrotizing myopathy (IMNM). Remimazolam has a similar chemical structure to midazolam but possesses a unique side chain that reduces its propensity to accu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogino, Hitoshi, Sugiyama, Daisuke, Ueda, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Anesthesiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168013/
https://www.ncbi.nlm.nih.gov/pubmed/37182089
http://dx.doi.org/10.7759/cureus.37326
Descripción
Sumario:We reported the anesthetic management of remimazolam, a novel ultra-short-acting benzodiazepine, for a 21-month-old female with immune-mediated necrotizing myopathy (IMNM). Remimazolam has a similar chemical structure to midazolam but possesses a unique side chain that reduces its propensity to accumulate in the body, thereby minimizing prolonged sedation or respiratory depression. Our experience supports that remimazolam could be a suitable agent for anesthetizing the patient with IMNM.

Ejemplares similares